Axicabtagene ciloleucel (Intravenous)
Medically reviewed by Drugs.com. Last updated on Mar 26, 2022.
Cytokine release syndrome and neurologic toxicitiesCytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving axicabtagene ciloleucel. Do not administer axicabtagene ciloleucel to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids .Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving axicabtagene ciloleucel, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with axicabtagene ciloleucel. Provide supportive care and/or corticosteroids as needed .Axicabtagene ciloleucel is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program .
Commonly used brand name(s)
In the U.S.
- Yescarta
Available Dosage Forms:
- Suspension
Therapeutic Class: Immunological Agent
Chemical Class: CAR T-Cell Agent
Uses for axicabtagene ciloleucel
Axicabtagene ciloleucel injection is used to treat follicular lymphoma and large B-cell lymphoma (including diffuse large B-cell lymphoma [DLBCL], primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, or DLBCL from follicular lymphoma) that has come back or after 2 or more lines of treatment did not work well.
Axicabtagene ciloleucel injection is an antineoplastic (cancer) medicine that is made from your own white blood cells, which have been modified to recognize and attack your cancer cells. Before you begin treatment, talk to your doctor about the benefits of axicabtagene ciloleucel as well as the possible risks of receiving it.
Axicabtagene ciloleucel is available only under a restricted distribution program called Yescarta® and Tecartus™ REMS (Risk Evaluation and Mitigation Strategy) Program.
Before using axicabtagene ciloleucel
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For axicabtagene ciloleucel, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to axicabtagene ciloleucel or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of axicabtagene ciloleucel injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of axicabtagene ciloleucel injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
